Cohort 1 | TCGA | |||
---|---|---|---|---|
No. of patients | % | No. of patients | % | |
No. of patients | 55 | 452 | ||
Sex | ||||
Male | 37 | 67.3 | 290 | 64.2 |
Female | 18 | 32.7 | 162 | 35.8 |
Age median (range) | 70 (32–84) | 61 (29–90) | ||
Stage | ||||
1 | 24 | 43.6 | 221 | 48.9 |
2 | 3 | 5.5 | 44 | 9.7 |
3 | 14 | 25.5 | 116 | 25.7 |
4 | 14 | 25.5 | 69 | 15.3 |
NA | – | – | 2 | 0.4 |
Primary tumor | ||||
1 | 26 | 47.3 | 227 | 50.2 |
2 | 4 | 7.3 | 56 | 12.4 |
3 | 24 | 43.6 | 164 | 36.3 |
4 | 1 | 1.8 | 5 | 1.1 |
N | ||||
0 | 46 | 83.6 | 203 | 44.9 |
1/2 | 7 | 12.7 | 11 | 2.4 |
X | 2 | 3.6 | 238 | 52.7 |
M | ||||
0 | 42 | 76.4 | 377 | 83.4 |
1 | 13 | 23.6 | 68 | 15.0 |
X | – | – | 7 | 1.5 |
G | ||||
1 | 8 | 14.5 | 10 | 2.2 |
2 | 38 | 69.1 | 188 | 41.6 |
3/4 | 9 | 16.4 | 251 | 55.5 |
X | – | – | 1 | 0.2 |
NA | – | – | 2 | 0.4 |
Median follow-up time [years] (range) | 2.9 (0–10.1) | 3.5 (0–12.4) | ||
Overall survivala [years] | ||||
Deceased | 28 | 50.9 | 145 | 32.1 |
Alive | 26 | 47.3 | 307 | 67.9 |